Comparing the rectal Indomethacin plus vitamin C injection versus rectal indomethacin on prevention of post ERCP pancreatitis

Effect of indomethacin suppository plus vitamin C injection verusus indomethacin suppository in prevention of post ERCP pancreatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N11

Enrollment

280

Registered

2021-04-04

Start date

2021-05-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatitis. Other acute pancreatitis

Interventions

Group1: Adminstration of single dose of 100 mg rectal indomethacine just before doing Endoscopic cholangiopancreatography Group2: Administration of single dose of 100 mg rectal Indomethacine plus 500

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing ERCP in Taleghani hospital by taking written consent

Exclusion criteria

Exclusion criteria: Patients history of hypersensitivity against each of indomethacin or vitamin C Active peptic ulcer diseases Renal impairment (GFR < 10 ml/min)

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: 10 days after doing ERCP. Method of measurement: clinical evaluation.	—

Secondary

Measure	Time frame
Gastrointestinal bleeding. Timepoint: 10 days after doing ERCP. Method of measurement: Clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026